<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analysed the outcome and hospitalization requirements of the first 100 patients (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), N=13; <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM), N=14; CLL, N=12; non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), N=17; <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), N=18; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, N=24 and <z:mp ids='MP_0005481'>CML</z:mp>, N=2) treated in Denmark with haematopoietic cell transplantation after non-myeloablative conditioning with TBI 2 Gy+/-fludarabine </plain></SENT>
<SENT sid="1" pm="."><plain>The cumulative incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grade II-IV and extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 67 and 49% </plain></SENT>
<SENT sid="2" pm="."><plain>After a median follow-up of 534 days, the overall survival, PFS, relapse-related mortality and treatment-related mortality were 59, 50, 25 and 17%, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with CLL, NHL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with &lt;5% blasts at any time had a favourable outcome with a PFS of 61-71% </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with MM, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and a history of &gt; or =5% blasts had a less favourable outcome with a PFS of 19-38% (P=0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative incidence of discontinuation of immunosuppression was 37% </plain></SENT>
<SENT sid="6" pm="."><plain>During the first and second year post transplant, patients experienced a mean of 41 and 13 outpatient clinic visits, and 53 and 16 days of hospitalization </plain></SENT>
<SENT sid="7" pm="."><plain>Sixteen patients were admitted to the intensive care unit, of whom eight are still alive </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, transplantation outcomes were encouraging, but complications requiring admission and outpatient clinic visits occur frequently post transplant </plain></SENT>
</text></document>